No Data
No Data
PURUISI (301257.SZ): Received the proposal for the mid-2024 dividend from the company's actual controlling shareholder and director.
On July 18th, Gr8est7i (301257.SZ) announced that in order to promote the shared operating development benefits for all shareholders, and practice the development concept of "investors first" based on long-term confidence in the company's development, enhance investor return levels, promote high-quality development of listed companies, and effectively protect the interests of the vast number of investors, the company's 2023 Annual Shareholders' Meeting has been held on May 20, 2024, and has approved the proposal of "Requesting the Board of Directors to Authorize the Mid-Term Dividend Plan". The company agrees to pay a mid-term dividend for the year 2024 while meeting the conditions for profit distribution.
Puruisi (301257.SZ): main customers are international pharmaceutical companies or well-known domestic innovative pharmaceutical companies.
Prussia (301257.SZ) stated on the investor interaction platform on June 27th that its main customers are international pharmaceutical companies or well-known domestic innovative pharmaceutical companies. As one of the earliest companies to enter the SMO industry in China, the company has become a qualified supplier for many well-known domestic and foreign pharmaceutical companies and CRO clients such as Novo Nordisk, Merck, Roche, Mandy, Abbott, Pfizer, Johnson & Johnson, Lilly, Jingding, Bayer, GlaxoSmithKline, AstraZeneca, Fuqirui, Hengrui, Kangfang, and Zhongda Tianqing, thanks to its professional service capabilities.
At present, the main orders of Puris (301257.SZ) are mainly for innovative drug projects of MNCs, domestic large pharmaceutical companies, and listed Biotech type customers.
On June 21, Gelunhui, Pruce's (301257.SZ) recently conducted an investor survey. In response to the question of whether the company's market strategy would be adjusted due to the uncertainty of new order signing under the external environment, the company replied that it would establish the goal of signing new orders for 2024 based on the pipeline of each applicant at the beginning of each year. Currently, orders are still mainly for innovative drug projects of MNCs, domestic large pharmaceutical companies and listed Biotech type customers, and specific new order data will be disclosed every half year. According to the latest market situation, the company's BD continuously adjusts its strategy on a weekly, monthly, and quarterly basis and actively expands.
There's No Escaping SMO ClinPlus CO.,LTD.'s (SZSE:301257) Muted Earnings
SMO ClinPlus CO.,LTD.'s (SZSE:301257) price-to-earnings (or "P/E") ratio of 17.8x might make it look like a buy right now compared to the market in China, where around half of the companies have P/E r
Prius (301257.SZ): 2023 equity distribution of 10 to 3 transfers of 1.66 yuan Equity Registration Date June 5
On May 29, GLONGHUI (301257.SZ) announced that the company's 2023 equity distribution plan is to distribute 1.660000 yuan in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital of 61,160,000 shares. At the same time, the capital reserve fund will be used to transfer 3.000000 shares to all shareholders for every 10 shares. The share registration date for this equity distribution is June 5, 2024, and the ex-dividend date is June 6, 2024.
Major shareholders of Prius (301257.SZ) believe Zhaotai will reduce its holdings by 1%
Prius (301257.SZ) announced that Shanghai Guanyu Investment and Development Co., Ltd., the shareholder of the company holds more than 5% of the shares - Guan...
No Data